Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K R Herrlinger

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Alimentary Pharmacology & Therapeutics|November 4, 2006
Review article: interactions between genotype and response to therapy in inflammatory bowel diseasesK R Herrlinger, D P Jewell
International Journal of Pancreatology : Official Journal of the International Association of Pancreatology|August 22, 2000
The pancreas and inflammatory bowel diseasesK R Herrlinger, E F Stange
Innere Medizin (Heidelberg, Germany)|December 23, 2024
[New treatment targets for inflammatory bowel disease?]K R Herrlinger, E F Stange
Journal of Crohn'S & Colitis|December 3, 2010
Two cases of fatal Pneumocystis jirovecii pneumonia as a complication of tacrolimus therapy in ulcerative colitis--a need for prophylaxisM Escher, E F Stange, K R Herrlinger
Deutsche Medizinische Wochenschrift (1946)|February 2, 2012
[Histoplasmosis: uncommon opportunistic infection in a patient with HIV infection]M Escher, T M Kainikkara, A Grabner, et al.
The American Journal of Gastroenterology|February 28, 2002
Alterations in pulmonary function in inflammatory bowel disease are frequent and persist during remissionK R Herrlinger, M K Noftz, K Dalhoff, et al.
Alimentary Pharmacology & Therapeutics|February 24, 2001
Minimal renal dysfunction in inflammatory bowel disease is related to disease activity but not to 5-ASA useK R Herrlinger, M K Noftz, K Fellermann, et al.
Medizinische Klinik (Munich, Germany : 1983)|March 20, 2001
[Sweet syndrome and erythema nodosum in ulcerative colitis, refractory to steroids: successful treatment with tacrolimus]K Fellermann, B Rudolph, T Witthöft, et al.
Alimentary Pharmacology & Therapeutics|June 26, 2003
Remission maintenance by tioguanine in chronic active Crohn's diseaseK R Herrlinger, P Deibert, M Schwab, et al.
Clinical Pharmacology and Therapeutics|February 4, 2011
ABCB1 single-nucleotide polymorphisms determine tacrolimus response in patients with ulcerative colitisK R Herrlinger, H Koc, S Winter, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Alimentary Pharmacology & Therapeutics|November 4, 2006
Review article: interactions between genotype and response to therapy in inflammatory bowel diseasesK R Herrlinger, D P Jewell
International Journal of Pancreatology : Official Journal of the International Association of Pancreatology|August 22, 2000
The pancreas and inflammatory bowel diseasesK R Herrlinger, E F Stange
Innere Medizin (Heidelberg, Germany)|December 23, 2024
[New treatment targets for inflammatory bowel disease?]K R Herrlinger, E F Stange
Journal of Crohn'S & Colitis|December 3, 2010
Two cases of fatal Pneumocystis jirovecii pneumonia as a complication of tacrolimus therapy in ulcerative colitis--a need for prophylaxisM Escher, E F Stange, K R Herrlinger
Deutsche Medizinische Wochenschrift (1946)|February 2, 2012
[Histoplasmosis: uncommon opportunistic infection in a patient with HIV infection]M Escher, T M Kainikkara, A Grabner, et al.
The American Journal of Gastroenterology|February 28, 2002
Alterations in pulmonary function in inflammatory bowel disease are frequent and persist during remissionK R Herrlinger, M K Noftz, K Dalhoff, et al.
Alimentary Pharmacology & Therapeutics|February 24, 2001
Minimal renal dysfunction in inflammatory bowel disease is related to disease activity but not to 5-ASA useK R Herrlinger, M K Noftz, K Fellermann, et al.
Medizinische Klinik (Munich, Germany : 1983)|March 20, 2001
[Sweet syndrome and erythema nodosum in ulcerative colitis, refractory to steroids: successful treatment with tacrolimus]K Fellermann, B Rudolph, T Witthöft, et al.
Alimentary Pharmacology & Therapeutics|June 26, 2003
Remission maintenance by tioguanine in chronic active Crohn's diseaseK R Herrlinger, P Deibert, M Schwab, et al.
Clinical Pharmacology and Therapeutics|February 4, 2011
ABCB1 single-nucleotide polymorphisms determine tacrolimus response in patients with ulcerative colitisK R Herrlinger, H Koc, S Winter, et al.
Pageof 3